Physician profile
Michael Bavlsik
NPI 1295752756
$757.01
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $325 · 2020: $66.72 · 2021: $73.06 · 2022: $105 · 2023: $187.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $187.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $187.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $126.88 | 2019-2022 | |
| Pfizer INC. | $115.97 | 2019-2023 | |
| Abbvie INC. | $112.00 | 2019-2021 | |
| Glaxosmithkline, LLC. | $60.40 | 2019-2023 | Arexvy, Shingrix, Trelegy Ellipta |
| Novo Nordisk INC | $50.55 | 2023 | Wegovy |
| Scilex Pharmaceuticals INC. | $45.52 | 2019 | |
| Lilly USA, LLC | $40.86 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $29.02 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $28.16 | 2023 | Nuedexta |
| Exact Sciences Corporation | $24.70 | 2023 | Cologuard Collection Kit |
| Abbott Laboratories | $24.67 | 2023 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.53 | 2022 | |
| Janssen Pharmaceuticals, INC | $14.69 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $13.21 | 2022 | |
| Allergan, INC. | $13.00 | 2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $12.17 | 2020 | |
| Novartis Pharmaceuticals Corporation | $11.90 | 2019 | |
| Amarin Pharma, INC. | $11.78 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Bavlsik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.